Patients with long-chain fatty oxidation disorders (LC-FAODs) have historically been treated with diet modification and even-carbon medium-chain triglyceride (MCT) supplementation. In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs. Triheptanoin is an odd-carbon MCT designed to bypass the metabolic block in LC-FAODs, recently approved as an alternative treatment option. The faculty discuss the safety and efficacy of triheptanoin and their real-world experience initiating and optimizing it to bridge critical care gaps in patients with LC-FAODs. They briefly orient learners to a downloadable, point-of-care resource for patient education developed as part of this accredited activity.

Patients with long-chain fatty oxidation disorders (LC-FAODs) have historically been treated with diet modification and even-carbon medium-chain triglyceride (MCT) supplementation. In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs. Triheptanoin is an odd-carbon MCT designed to bypass the metabolic block in LC-FAODs, recently approved as an alternative treatment option. The faculty discuss the safety and efficacy of triheptanoin and their real-world experience initiating and optimizing it to bridge critical care gaps in patients with LC-FAODs. They briefly orient learners to a downloadable, point-of-care resource for patient education developed as part of this accredited activity.

Patients with long-chain fatty oxidation disorders (LC-FAODs) have historically been treated with diet modification and even-carbon medium-chain triglyceride (MCT) supplementation. In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs. Triheptanoin is an odd-carbon MCT designed to bypass the metabolic block in LC-FAODs, recently approved as an alternative treatment option. The faculty discuss the safety and efficacy of triheptanoin and their real-world experience initiating and optimizing it to bridge critical care gaps in patients with LC-FAODs. They briefly orient learners to a downloadable, point-of-care resource for patient education developed as part of this accredited activity.